Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]F-DED is a radiopharmaceutical positron emission tomography (PET) imaging agent. It is a deuterated derivative of deprenyl labeled with fluorine-18 and was specifically designed to target monoamine oxidase B (MAO-B), an enzyme that is upregulated in reactive astrocytes during neuroinflammation. By binding preferentially to areas with increased MAO-B activity, [18F]F-DED enables non-invasive visualization and quantification of reactive astrogliosis—a hallmark of neuroinflammatory processes—in the brain. This tracer has shown promise for assessing neuroinflammation in Alzheimer's disease and other neurological disorders, providing insights into disease progression and the role of astrocyte activation in neurodegeneration[3][4][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]F-DED.